Mikel Berdud

Dr. Mikel Berdud is an economist specializing in pharmaceutical R&D incentives, pricing and reimbursement, and the social value of innovation. He has six years of teaching and research experience in the Department of Economics at the Public University of Navarre. Mikel holds a PhD in the economics of organizations and behavioral economics, where he developed and tested economic models of financial and non-financial incentives for intrinsically motivated agents.

Mikel joined the Office of Health Economics (OHE) in 2015 and is currently a Senior Principal Economist and a team member of the Economics of Innovation theme. His research focuses on the role of intellectual property rights and other pull/push incentives in driving pharmaceutical innovation, the regulation of pharmaceutical markets and its effects on access and R&D investment, and the impact of value-based pricing and other innovative pricing models in fostering innovation and maximizing social welfare. He also explores the role of competition—both on- and off-patent—in improving access to and affordability of pharmaceutical innovation, as well as issues surrounding price transparency for new health technologies. In addition to his role at OHE, he is a visiting researcher at the Public University of Navarre (UPNA).

Mikel’s recent and ongoing research includes analysing the life-cycle value of medicines, the social surplus generated by new health technologies and its distribution, and the economics of antimicrobial resistance, including push and pull incentive mechanisms for new antibiotics. His work also examines regulations and incentives for orphan medicinal products, economic efficiency in generic and biosimilar markets, the economics of curative treatments (e.g., hepatitis C drugs), and the impact of pharmaceutical market regulations (such as VPAS) and cost-effectiveness thresholds on innovation, health system sustainability, and social welfare.